- Report
- February 2024
- 70 Pages
North America
From €4230EUR$4,750USD£3,692GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4230EUR$4,750USD£3,692GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4230EUR$4,750USD£3,692GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4230EUR$4,750USD£3,692GBP
- Report
- August 2023
- 150 Pages
North America
From €4230EUR$4,750USD£3,692GBP
- Report
- October 2022
- 70 Pages
Africa
From €4230EUR$4,750USD£3,692GBP
- Report
- June 2025
- 250 Pages
Canada
From €2484EUR$2,789USD£2,168GBP
- Report
- August 2024
- 150 Pages
Global
From €2484EUR$2,789USD£2,168GBP
- Report
- May 2023
- 147 Pages
Global
From €4407EUR$4,949USD£3,846GBP
- Report
- March 2025
- 50 Pages
Kenya
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Egypt
From €534EUR$600USD£466GBP
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Greece
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Finland
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Denmark
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Norway
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Austria
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Ireland
From €534EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Sweden
From €534EUR$600USD£466GBP

Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more